Latest Health News

Aurum Resources Limited has had its trading suspension lifted immediately following the lodgement of its annual financial report, allowing its shares to resume trading on the ASX.

Echo IQ reports a remarkable 153% increase in echocardiogram processing through its EchoSolv AS platform in the US, with a Mayo Clinic validation study nearing completion ahead of a critical FDA submission. The company is also advancing European market entry and strengthening its advisory team to accelerate global growth.

Orion Minerals Ltd has been reinstated to ASX quotation following the release of its 2025 annual report and a new capital raising announcement, ending its trading suspension.

Australian Unity Limited has opened a $101 million non-renounceable entitlement offer alongside a $160 million placement, aiming to strengthen its balance sheet and support ongoing acquisitions. The company also announced the appointment of Kelly Bayer Rosmarin as its next CEO, signaling a new chapter in leadership.

ImpediMed secures expanded insurance reimbursement for its SOZO platform, now covering over 301 million US lives and enhancing early detection of breast cancer-related lymphedema.

BPH Global Ltd will lift its trading suspension on 2 October 2025 following the lodgement of its annual financial report for the year ended 30 June 2025.

DGR Global Limited will have its trading suspension lifted on 2 October 2025 following the lodgement of its annual report, marking a key step back to market normalcy.

CONNEQT Health has raised $2 million through a convertible note facility with a director-owned entity, providing fresh capital to support its growth plans. Shareholder approval will be key to unlocking the full benefits of this funding.

Anatara Lifesciences has raised $1.2 million through a discounted share placement to fund its Anti-Obesity project and explore new opportunities. The capital injection reflects strong institutional support amid ongoing pipeline development.

OMG Group Limited has reported a remarkable 114% year-on-year increase in net sales for Q1 FY26, driven by robust ecommerce growth and expanding retail partnerships.

EVE Health Group has reached a pivotal milestone with the first patient prescriptions of Dyspro™, its cannabinoid-based treatment for dysmenorrhoea and endometriosis, alongside launching an educational platform to support patients and clinicians.

Biome Australia Limited has reported a record-breaking $5.94 million in sales revenue for Q1 FY26, surpassing forecasts and accelerating toward its ambitious Vision 27 revenue goals.